HC Wainwright Has Lowered Expectations for Humacyte (NASDAQ:HUMA) Stock Price

Key Points

• Humacyte's price target was reduced by analysts at HC Wainwright from $4.00 to $3.00, indicating a potential upside of 71.43% from the current stock price.
• Despite the price target cut, Humacyte maintains a "buy" rating from HC Wainwright, while other analysts have set various price targets, with an average of $11.57.
• The company reported an earnings per share of ($0.10), beating expectations, and has shown significant increases in institutional buying, with positions up by over 85% for some investors.

Humacyte (NASDAQ:HUMA - Free Report) had its target price lowered by HC Wainwright from $4.00 to $3.00 in a research report released on Tuesday morning,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Humacyte's Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.75) EPS, FY2026 earnings at ($0.67) EPS, FY2027 earnings at ($0.43) EPS, FY2028 earnings at $0.03 EPS and FY2029 earnings at $0.30 EPS.

Several other equities analysts also recently issued reports on the stock. Benchmark decreased their price objective on shares of Humacyte from $17.00 to $14.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Wall Street Zen raised shares of Humacyte from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Finally, D. Boral Capital reaffirmed a "buy" rating and set a $25.00 price objective on shares of Humacyte in a report on Monday. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $10.64.

Humacyte Stock Performance

NASDAQ HUMA traded up $0.10 during mid-day trading on Tuesday, reaching $1.88. 6,543,798 shares of the stock were exchanged, compared to its average volume of 5,794,437. The business's 50 day moving average is $2.33 and its 200-day moving average is $2.48. Humacyte has a 1 year low of $1.15 and a 1 year high of $7.48. The company has a market capitalization of $291.63 million, a P/E ratio of -4.18 and a beta of 1.90. The company has a debt-to-equity ratio of 2.97, a quick ratio of 3.28 and a current ratio of 2.45.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). The company had revenue of $0.30 million for the quarter, compared to analysts' expectations of $0.94 million. On average, equities research analysts forecast that Humacyte will post -1.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Humacyte

A number of institutional investors and hedge funds have recently bought and sold shares of HUMA. Vanguard Group Inc. boosted its position in Humacyte by 10.8% during the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company's stock worth $28,294,000 after acquiring an additional 543,995 shares during the last quarter. Geode Capital Management LLC boosted its position in Humacyte by 4.7% during the fourth quarter. Geode Capital Management LLC now owns 2,135,133 shares of the company's stock worth $10,785,000 after acquiring an additional 94,915 shares during the last quarter. Wells Fargo & Company MN boosted its position in Humacyte by 40.9% during the fourth quarter. Wells Fargo & Company MN now owns 50,454 shares of the company's stock worth $255,000 after acquiring an additional 14,649 shares during the last quarter. Legal & General Group Plc boosted its position in Humacyte by 19.5% during the fourth quarter. Legal & General Group Plc now owns 81,405 shares of the company's stock worth $411,000 after acquiring an additional 13,293 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Humacyte during the fourth quarter worth about $377,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.